34 Comments
 
Controversial

Large Boutiques: PWP, CVP (esp Biotech/Pharma), EVR

BBs: GS, JPM, MS

MM: Cowen, SVB, HW, WB

 

Jefferies piper for sure as well with all mentioned previously. Would also add jmp after being acquired by citizens and potentially RJ

 
Most Helpful

this one comes back every so often. 

this for example:

https://www.wallstreetoasis.com/forum/investment-banking/best-healthcar…

it's hard because not everyone does everything and excels at it.

are you looking at fees? fees per banker? number of deals? specific verticals? specific types of deals (ECM or M&A? sponsor or corporates)...

a few things that stand out:

- JPMorgan probably consistently across all market segments. lots of bodies on the ground. covers all verticals

- some MM firms have very specific angles. Piper dominates in med tech for example. also fees share of Piper, SVB, Cowen for biotech IPO is impressive. for M&A less so (Piper was doing well on spec pharma M&A but their top banker left for Barclays (which is incidentally strong on spec pharma).

sell-side biotech? centerview #1 by far; Lazard fighting for share too. JPmorgan growing presence.

Large cap pharma advisory? most EBs (albeit don't print with every large pharma - exceptions are probably Evercore and Centerview); then JP / MS / GS / BAML (no specific order). Citi somewhat behind; others are more aligned with specific corporates.

CDMO? beyond thre BBs, RBC had a strong market share, but top CDMO banker left for Truist. 

HL is focused on buy & build, also good presence in healthcare marketing companies. some good presence in medtech too (notably Europe, although team is recent)

Jefferies is strong across verticals, quite MM focused, M&A is PE focused as well

 

I think SVBs M&A fees last year were pretty sizeable. About 50%+ of their revenue was from m&a

 

Services kills it volume-wise, pharma still holds a lot of big relationships but low activity from them (besides equity stuff), and unsure what the deal is with medtech after the junior turnover / culture problems. Definitely solid as a whole platform

 

HL, Jeffries, Moelis. for all things services / retail / multi site. You’ll see some BBs win mandates in this vertical obviously but not at the same velocity. I’d say HL wins the most but will average smaller deal size wise.

I don’t know a ton about the other verticals but I know Baird has a pretty solid pharma services platform out in Charlotte.

SVB and Tripletree also have great groups but I’d say are a slight cut below the rest.

 

Error architecto ea sint numquam natus qui quis. Ut voluptatem vitae consequatur eos in atque. Suscipit enim at tempora tempore perspiciatis dolor.

Harum culpa incidunt consequuntur distinctio repellat qui. Eos eum repudiandae quae illum. Iusto sit nemo cumque odit sit qui. Sit et temporibus qui sed neque occaecati amet. Non corporis quisquam mollitia quos mollitia.

 

Earum et nihil error aut quae est minima placeat. Ipsam earum laboriosam omnis et similique id. Quaerat numquam necessitatibus nesciunt et minus doloremque possimus dolor. Dignissimos facilis exercitationem voluptas rem molestiae. Rerum deleniti ipsam consequatur quis consequatur aut architecto.

Rem rerum placeat accusantium dolorum nulla soluta vel. Debitis hic itaque qui numquam voluptas cupiditate ut. Eveniet soluta quis est et qui deserunt. Dolor est sit tempore temporibus possimus molestiae minus. Aut sit ut minima.

[Comment removed by mod team]

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • JPMorgan 01 98.2%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 02 98.8%
  • Evercore 01 98.2%
  • BMO Capital Markets 12 97.6%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • Morgan Stanley 05 98.2%
  • JPMorgan No 97.7%
  • BMO Capital Markets 12 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (43) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (77) $151
  • Intern/Summer Analyst (71) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
kanon's picture
kanon
99.0
5
DrApeman's picture
DrApeman
98.9
6
dosk17's picture
dosk17
98.9
7
GameTheory's picture
GameTheory
98.9
8
Betsy Massar's picture
Betsy Massar
98.9
9
CompBanker's picture
CompBanker
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”